Crossmark

Characteristics of insulin-Naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials

Crossref DOI link: https://doi.org/10.1186/s40842-018-0059-2

Published Online: 2018-05-08

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cummings, M. H.

Cao, D.

Hadjiyianni, I.

Ilag, L. L. http://orcid.org/0000-0001-8831-9726
Tan, M. H.
Funding

Funding for this research was provided by:

Eli Lilly and Company
License Information

Text and Data Mining valid from 2018-05-08
More Information

Article History

Received: 27 October 2017

Accepted: 4 April 2018

First Online: 8 May 2018

Ethics approval and consent to participate

: Not applicable.

: MHC has participated in Abasaglar speaker events for which he received honorarium from Eli Lilly and Company and Boehringer-Ingelheim. LLI, DC, and IH are employees of and hold stock in Eli Lilly and Company. MHT is a retiree of Eli Lilly and Company. This study was previously published in part as two abstracts, the first at the American Diabetes Association’s 76th Annual Scientific Sessions in New Orleans, LA, USA in June 2016 and the second at Diabetes UK Professional Conference, Manchester, UK in March 2017.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below